Opioid free regimens - Revision history

Danbot: Add See Also section

2026-03-22T09:13:27Z

Add See Also section

← Older revision		Revision as of 09:13, 22 March 2026
Line 77:		Line 77:
	*During above study, a challenge was managing staff that had little experience in using medications for off label uses.		*During above study, a challenge was managing staff that had little experience in using medications for off label uses.
	*Certain subsets of patients will have various contraindications that will need to be considered such as patients with cardiovascular disease and NSAIDs. Those contraindications will not be reviewed on this page.		*Certain subsets of patients will have various contraindications that will need to be considered such as patients with cardiovascular disease and NSAIDs. Those contraindications will not be reviewed on this page.

			==See Also==
			*[[Acute pain management]]
			*[[Opioids]]
			*[[Nonsteroidal anti-inflammatory drugs]]
			*[[Ketamine]]

	==References==		==References==

Elcatracho: /* Headache */

2020-11-29T17:59:06Z

Headache

← Older revision		Revision as of 17:59, 29 November 2020
Line 35:		Line 35:
	*IV [[Ketorolac]] 10-15 mg or IV Diclofenac 75 mg or IV Metimazole 1 g		*IV [[Ketorolac]] 10-15 mg or IV Diclofenac 75 mg or IV Metimazole 1 g
	*US Guided nerve block, Paracervical trigger point injections with 2% Lidocaine or 0.5% Bupivacaine		*US Guided nerve block, Paracervical trigger point injections with 2% Lidocaine or 0.5% Bupivacaine
	*IV [[Haloperidol]] 2.5 mg, IV Droperidol 2-5 mg (slow infusion over 10 min)		*IV [[Haloperidol]] 2.5 mg, IV [[Droperidol]] 2-5 mg (slow infusion over 10 min)
	*IV [[Propofol]] (intractable migraine) 10 mg IVP q5 minutes		*IV [[Propofol]] (intractable migraine) 10 mg IVP q5 minutes
	*Refractory cases - [[Ketamine]] 0.2-0.3 mg/kg short infusion		*Refractory cases - [[Ketamine]] 0.2-0.3 mg/kg short infusion

ClaireLewis at 20:08, 22 September 2019

2019-09-22T20:08:28Z

← Older revision		Revision as of 20:08, 22 September 2019
Line 49:		Line 49:
	*IV [[Lidocaine]] 1.5 mg/kg of 2% over 10-15 minutes, + continuous infusion at 1.5-2.5 mg/kg/hour		*IV [[Lidocaine]] 1.5 mg/kg of 2% over 10-15 minutes, + continuous infusion at 1.5-2.5 mg/kg/hour
	*IV [[Dexmedetomidine]] 02.-0.3 mcg/kg/hour IV infusion		*IV [[Dexmedetomidine]] 02.-0.3 mcg/kg/hour IV infusion
			*[[Gabapentin]] (not included in Motov/Lyness regimen)
			**Day 1: 300mg PO qDay
			**Day 2: 300mg PO q12hr
			**Day 3: 300mg PO q8hr

	===[[Renal Colic]]===		===[[Renal Colic]]===

ClaireLewis: /* References */

2019-09-22T17:33:38Z

References

← Older revision		Revision as of 17:33, 22 September 2019
Line 78:		Line 78:

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Palliative Medicine]]

Kxl328: /* Sickle Cell Pain Crisis */

2018-03-01T23:40:40Z

Sickle Cell Pain Crisis

← Older revision		Revision as of 23:40, 1 March 2018
Line 57:		Line 57:
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour

	===[[Sickle Cell]] ~~Pain Crisis~~===		===[[Sickle Cell Crisis]]===
	*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)		*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour

Kxl328: /* Sickle cell */

2018-03-01T23:39:56Z

Sickle cell

← Older revision		Revision as of 23:39, 1 March 2018
Line 57:		Line 57:
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour

	===[[Sickle ~~cell~~]]===		===[[Sickle Cell]] Pain Crisis===
	*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)		*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour

Kxl328: /* Renal Colic */

2018-03-01T23:39:38Z

Renal Colic

← Older revision		Revision as of 23:39, 1 March 2018
Line 57:		Line 57:
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour

	~~--[[User:Kxl328\|Kevin Lu]] ([[User talk:Kxl328\|talk]]) 23:38, 1 March 2018 (UTC)~~===[[Sickle ~~Cell Crisis\|Sickle Cell Vaso-Occlusive Crisis~~]]===		===[[Sickle cell]]===
	*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)		*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour

Kxl328: /* Sickle Cell Vaso-Occlusive Crisis */

2018-03-01T23:38:23Z

Sickle Cell Vaso-Occlusive Crisis

← Older revision		Revision as of 23:38, 1 March 2018
Line 57:		Line 57:
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour

	===[[Sickle Cell Crisis\|Sickle Cell Vaso-Occlusive Crisis]]===		--[[User:Kxl328\|Kevin Lu]] ([[User talk:Kxl328\|talk]]) 23:38, 1 March 2018 (UTC)===[[Sickle Cell Crisis\|Sickle Cell Vaso-Occlusive Crisis]]===
	*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)		*IN [[Ketamine]] 1 mg/kg (no more than 1 ml per nostril)
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour and SQ infusion at 0.15-0.25 mg/kg/hour
	*IV/IM [[Haloperidol]] or Droperidol]] 5-10 mg		*IV/IM [[Haloperidol]] or [[Droperidol]] 5-10 mg
	*IV [[Dexmedetomidine]] 02.-0.3 mcg/kg/hour continuous infusion		*IV [[Dexmedetomidine]] 02.-0.3 mcg/kg/hour continuous infusion

Kxl328: /* MSK */

2017-04-05T01:54:06Z

MSK

← Older revision		Revision as of 01:54, 5 April 2017
Line 42:		Line 42:
	*US guided nerve block		*US guided nerve block
	*IV [[Ketorolac]] 10-15 mg or IV Diclofenac 75 mg or IV Metimazole 1 g		*IV [[Ketorolac]] 10-15 mg or IV Diclofenac 75 mg or IV Metimazole 1 g
	*IV [[Acetaminophen 1g over 15 minutes		*IV [[Acetaminophen]] 1g over 15 minutes
	*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour		*IV [[Ketamine]] 0.3 mg/kg over 10 minutes, + IV drip at 0.15 mg/kg/hour

Neil.m.young: Text replacement - "* " to "*"

2016-10-27T16:34:03Z

Text replacement - "* " to "*"

← Older revision		Revision as of 16:34, 27 October 2016
Line 4:		Line 4:

	==Pharmacologic Options==		==Pharmacologic Options==
	Below are a series of recommendations outlined by Dr. Sergey Motov and Dr. David Lyness. <ref>* Lyness, D., & Motov, S. (2016, July 7). CERTA Opioid Alternatives and Analgesics. Retrieved July 25, 2016, from http://www.propofology.com/infographs/certa-opioid-alternatives-as-analgesics</ref>		Below are a series of recommendations outlined by Dr. Sergey Motov and Dr. David Lyness. <ref>*Lyness, D., & Motov, S. (2016, July 7). CERTA Opioid Alternatives and Analgesics. Retrieved July 25, 2016, from http://www.propofology.com/infographs/certa-opioid-alternatives-as-analgesics</ref>

	===[[Abdominal Pain]] (Non Traumatic)===		===[[Abdominal Pain]] (Non Traumatic)===
Line 71:		Line 71:

	Weaknesses:		Weaknesses:
	* During above study, a challenge was managing staff that had little experience in using medications for off label uses.		*During above study, a challenge was managing staff that had little experience in using medications for off label uses.
	* Certain subsets of patients will have various contraindications that will need to be considered such as patients with cardiovascular disease and NSAIDs. Those contraindications will not be reviewed on this page.		*Certain subsets of patients will have various contraindications that will need to be considered such as patients with cardiovascular disease and NSAIDs. Those contraindications will not be reviewed on this page.

	==References==		==References==